Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.

Three- and four-dimensional quantitative structure activity relationship (3D/4D-QSAR) pharmacophore models of competitive inhibitors of CYP2D6 were constructed using data from our laboratory or the literature. The 3D-QSAR pharmacophore models of the common structural features of CYP2D6 inhibitors were built using the program Catalyst (Molecular Simulations, San Diego, CA, USA). These 3D-QSAR models were compared with 3D and 4D-QSAR partial least squares (PLS) models which were constructed using molecular surface-weighted holistic invariant molecular (MS-WHIM) descriptors of size and shape of inhibitors. The first Catalyst model was generated from multiple conformers of competitive inhibitors (n = 20) of CYP2D6 mediated bufurolol 1'-hydroxylation. This model demonstrated a correlation of observed and predicted Ki (apparent) values of r = 0.75. A second Catalyst model was constructed from literature derived Ki (apparent) values (n = 31) for the inhibition of CYP2D6. This model provided a correlation of observed and predicted inhibition for CYP2D6 of r = 0.91. Both Catalyst Ki pharmacophores were then validated by predicting the Ki (apparent) of a test set of known CYP2D6 inhibitors (n = 15). Ten out of 15 of these Ki (apparent) values were predicted to be within one log residual of the observed value using our CYP2D6 inhibitor model, while the literature model predicted nine out of 15 values. Similarly, 3D- and 4D-QSARs derived from PLS MS-WHIM for our dataset yielded predictable models as assessed using cross-validation. The corresponding cross-validated PLS MS-WHIM model for the literature dataset yielded a comparable 3D-QSAR and improved 4D-QSAR value. Such computational models will aid in future prediction of drug-drug interactions.

[1]  A. J. Robinson,et al.  Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation. , 1997, Thrombosis research.

[2]  D A Smith,et al.  Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. , 1992, Biochemical pharmacology.

[3]  Robert L. Haining,et al.  Enzymatic Determinants of the Substrate Specificity of CYP2C9: Role of B‘−C Loop Residues in Providing the π-Stacking Anchor Site for Warfarin Binding† , 1999 .

[4]  Jeffrey P. Jones,et al.  Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[5]  K. Monostory,et al.  Ipriflavone as an inhibitor of human cytochrome P450 enzymes , 1998, British journal of pharmacology.

[6]  J. Miners,et al.  Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. , 1988, Biochemical pharmacology.

[7]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[8]  L. Li,et al.  Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. , 1998, Archives of biochemistry and biophysics.

[9]  D. Flockhart,et al.  Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[10]  T. Shimada,et al.  Structure and function of cytochrome P-450. , 1986, Advances in experimental medicine and biology.

[11]  G. Cruciani,et al.  Generating Optimal Linear PLS Estimations (GOLPE): An Advanced Chemometric Tool for Handling 3D‐QSAR Problems , 1993 .

[12]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.

[13]  Barry C. Jones,et al.  Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics , 1997 .

[14]  van der Hoeven Ta,et al.  Preparation and Properties of Partially Purified Cytochrome P-450 and Reduced Nicotinamide Adenine Dinucleotide Phosphate-Cytochrome P-450 Reductase from Rabbit Liver Microsomes , 1974 .

[15]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[16]  H. Kubinyi.  QSAR and 3D QSAR in drug design Part 2: applications and problems , 1997 .

[17]  Dennis A. Smith,et al.  Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates , 1997 .

[18]  S. Wrighton,et al.  Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation , 1997, European Journal of Clinical Pharmacology.

[19]  T. Leemann,et al.  Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. , 1993, Life sciences.

[20]  M H Tarbit,et al.  Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  S. Ekins,et al.  Autoactivation and activation of the cytochrome P450s. , 1998, International journal of clinical pharmacology and therapeutics.

[22]  S. Binkley,et al.  In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. , 1996, British journal of clinical pharmacology.

[23]  L. Wienkers,et al.  Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[24]  D. Abernethy,et al.  Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19 , 1997, Clinical pharmacology and therapeutics.